Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VLA 15

Next Previous
Drug Profile

VLA 15

Alternative Names: Borrelia vaccine - GlaxoSmithKline/Valneva; Lyme borreliosis vaccine - GlaxoSmithKline/Valneva; Lyme-borreliosis-vaccine-Valneva; Lyme-disease-vaccine-GlaxoSmithKline/Valneva; Lyme-disease-vaccine-Valneva; PF-07307405; VLA 15

Latest Information Update: 29 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intercell
  • Developer Pfizer; Valneva
  • Class Bacterial vaccines; Lyme disease vaccines; Subunit vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Lyme disease

Most Recent Events

  • 16 Oct 2024 Adverse events and immunogenicity data from a phase II VLA15-221 trial in Lyme disease (Prevention) released by Valneva and Pfizer
  • 04 Dec 2023 Pfizer and Valneva completes enrolment in the phase III VALOR trial in Lyme disease (In adolescents, In adults, In children, Prevention, In the elderly) in Germany, Finland, the Netherlands, Poland, Sweden, Estonia, Canada, USA (IM) (NCT05477524) (EudraCT2021-005427-20)
  • 07 Sep 2023 Safety and immunogenicity data from a phase II VLA15-221 trial in Lyme disease released by Valneva and Pfizer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top